Molecule Information

General Information of the Molecule (ID: Mol02168)

• Name: AFAP1 antisense RNA 1 (AFAP1-AS1) ,Homo sapiens
• Synonyms: AFAP1-AS1
• Molecule Type: LncRNA
• Gene Name: AFAP1-AS1
• Gene ID: 84740
• Location: chr4:7,754,077-7,778,928[+]
• Ensembl ID: ENSG00000272620
• HGNC ID: HGNC:28141

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Cisplatin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Non-small cell lung cancer [ICD-11: 2C25.0] [1], [2], [3], [4]

• Resistant Disease: Non-small cell lung cancer [ICD-11: 2C25.0]
• Resistant Drug: Cisplatin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: PI3K/AKT pathway; Regulation; N.A.
• In Vitro Model: A549 cells; Lung; Homo sapiens (Human); CVCL_0023
• In Vitro Model: A549 cells; Lung; Homo sapiens (Human); CVCL_0023
• In Vivo Model: Lung cancer patients; Homo sapiens
• Experiment for Molecule Alteration: RT-qPCR; Western blot; RNA immunoprecipitation
• Experiment for Drug Resistance: CCK8 assay; Colony formation assay; Cell cycle determination; Cell apoptosis determination; Transwell assay
• Mechanism Description: In conclusion, AFAP1-AS1 accelerates the proliferative and metastatic abilities of A549/DDP cells, whereas inhibits the apoptosis of A549/DDP cells, by interacting with EZH2 to activate the PI3K/AKT pathway; thus, inducing DDP resistance in NSCLC.

Investigative Drug(s) 1 drug(s) in total

DX-8951

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Disease Class: Breast adenocarcinoma [ICD-11: 2C60.1] [5]

• Resistant Disease: Breast adenocarcinoma [ICD-11: 2C60.1]
• Resistant Drug: DX-8951
• Molecule Alteration: Up-regulation; Interaction
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: BT474 cells; Breast; Homo sapiens (Human); CVCL_0179
• In Vitro Model: SK-BR-3 cells; Pleural effusion; Homo sapiens (Human); CVCL_0033
• In Vivo Model: Male BALB/c nude mice model; Mus musculus
• Experiment for Molecule Alteration: Knockdown assay; Microarray assay; Immunoprecipitation; FISH assay; qRT-PCR
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Exosomal AFAP1-AS1 could induce trastuzumab resistance through associating with AUF1 and promoting ERBB2 translation. Therefore, AFAP1-AS1 level may be useful for prediction of trastuzumab resistance and breast cancer treatment.

References

• Ref 1: MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition, migration and invasion by targeting ZEB2 in human hepatocellular carcinoma. Oncol Lett. 2020 Oct 20(4):23
• Ref 2: AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway. Oncol Lett. 2020 Jan;19(1):1024-1030
• Ref 3: Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. J Cell Mol Med. 2018 Sep;22(9):4253-4262
• Ref 4: High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Mol Carcinog. 2016 Dec;55(12):2095-2105
• Ref 5: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translationMol Cancer. 2020 Feb 5;19(1):26. doi: 10.1186/s12943-020-1145-5.